Publications by authors named "Uwe Trefzer"

Claim this Profile
A
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo Antonio Ascierto, Stefano Cascinu, Uwe Trefzer

Cancer Immunol Immunother· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.
Selma Ugurel, Carmen Loquai, Patrick Terheyden, Dirk Schadendorf, Erika Richtig, Uwe Trefzer

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D Lewis, Uwe Trefzer

J Am Acad Dermatol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Peter Mohr, Axel Hauschild, Uwe Trefzer, Alexander Enk, Wolfgang Tilgen

J Clin Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Michael R Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D Lewis, Uwe Trefzer

Lancet Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.
Uwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, Florian Schenck, Katharina C Kähler

J Immunother Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.
Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn, Uwe Trefzer

J Invest Dermatol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, Daniel J Treacy, Cory M Johannessen, Uwe Trefzer

Cancer Discov· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission of an intracardiac melanoma metastasis after tremelimumab therapy.
Sebastian Spethmann, Uwe Trefzer, Fabian Knebel

Case Rep Dermatol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Annette Degen, Michael Weichenthal, Selma Ugurel, Uwe Trefzer, Katharina Kilian

J Dtsch Dermatol Ges· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Paolo A Ascierto, David Minor, Antoni Ribas, Celeste Lebbe, Anne O'Hagan, Uwe Trefzer

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".
Annette Pflugfelder, Corinna Kochs, Andreas Blum, Marcus Capellaro, Christina Czeschik, Uwe Trefzer

J Dtsch Dermatol Ges· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Uwe Trefzer

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version.
Annette Pflugfelder, Corinna Kochs, Andreas Blum, Marcus Capellaro, Christina Czeschik, Uwe Trefzer

J Dtsch Dermatol Ges· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma.
Peter Mohr, Ulrik Birgersson, Carola Berking, Catriona Henderson, Uwe Trefzer

Skin Res Technol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GABAB receptor antibodies in paraneoplastic cerebellar ataxia.
Sven Jarius, Florian Steinmeyer, Astrid Knobel, Kaspar Streitberger, Benjamin Hotter, Uwe Trefzer

J Neuroimmunol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, Margaret A Marshall, Cornelis J A Punt, John B Haanen, Uwe Trefzer

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Georgina V Long, Uwe Trefzer, Michael A Davies, Richard F Kefford, Paolo A Ascierto

Lancet Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Individualized tumor therapy and status quo in melanoma].
Sebastian Bauer, Heinz Schmidberger, Uwe Trefzer

Onkologie· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Uwe Trefzer

N Engl J Med· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaginal fistula in a patient with relapsed ovarian cancer and amelanotic melanoma.
Mustafa Zelal Muallem, Sule Yildiz, Ruza Arsenic, Uwe Trefzer, Jalid Sehouli

Anticancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Maja A Hofmann, Axel Hauschild, Peter Mohr, Claus Garbe, Michael Weichenthal, Uwe Trefzer

Melanoma Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up.
Elisabeth Livingstone, Christine Windemuth-Kieselbach, Thomas K Eigentler, Rainer Rompel, Uwe Trefzer

Eur J Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Maja A Hofmann, Bernd Schicke, Andreas Fritsch, Susanne Biesold, Felix Gussmann, Uwe Trefzer

J Dermatol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Poulam M Patel, Stefan Suciu, Laurent Mortier, Wim H Kruit, Caroline Robert, Uwe Trefzer

Eur J Cancer· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis